Development of 18 F-Labeled PET Tracer Candidates for Imaging of the Abelson Non-receptor Tyrosine Kinase in Parkinson’s Disease
Journal of Medicinal Chemistry · 2023
DOI: 10.1021/acs.jmedchem.3c00902 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2023. Verfasst von E Johanna L Stéen und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology & Nuclear Medicine, Amsterdam UMC location, Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlan…. Hauptthemen laut MEDLINE: Fluorine Radioisotopes, Positron-Emission Tomography, Parkinson Disease, Proto-Oncogene Proteins c-abl. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 40 Literaturangaben.
Abstract (Originalsprache)
Activated Abelson non-receptor tyrosine kinase (c-Abl) plays a harmful role in neurodegenerative conditions such as Parkinson's disease (PD). Inhibition of c-Abl is reported to have a neuroprotective effect and be a promising therapeutic strategy for PD. We have previously identified a series of benzo[d]thiazole derivatives as selective c-Abl inhibitors from which one compound showed high therapeutic potential. Herein, we report the development of a complementary positron emission tomography (PET) tracer. In total, three PET tracer candidates were developed and eventually radiolabeled with fluorine-18 for in vivo evaluation studies in mice. Candidate [18F]3 was identified as the most promising compound, since it showed sufficient brain uptake, good washout kinetics, and satisfactory metabolic stability. In conclusion, we believe this tracer provides a good starting point to further validate and explore c-Abl as a target for therapeutic strategies against PD supported by PET.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Radiology & Nuclear Medicine, Amsterdam UMC location, Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.
- 1ST Biotherapeutics Inc. 240 Pangyoyeok-ro A-313, Bundang-gu, Seongnam-si, Gyeonggi-do 13493, Republic of Korea.
- Industry Alliance Office, Amsterdam UMC location, Vrije Universiteit Amsterdam, De Boelelaan 1085, 1081 HV Amsterdam, The Netherlands.
- Department of Pathology, Amsterdam UMC location, Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.
ORCID-Profile: E Johanna L Stéen, Wissam Beaino, Prisca Leferink, Albert D Windhorst
Zitieren
APA
Stéen, E. J. L., Park, A. Y., Beaino, W., Gadhe, C. G., Kooijman, E., Schuit, R. C., Schreurs, M., Leferink, P., Hoozemans, J. J. M., Kim, J. E., Lee, J., & Windhorst, A. D. (2023). Development of 18 F-Labeled PET Tracer Candidates for Imaging of the Abelson Non-receptor Tyrosine Kinase in Parkinson’s Disease. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.3c00902
Vancouver
Stéen EJL, Park AY, Beaino W, Gadhe CG, Kooijman E, Schuit RC, et al. Development of 18 F-Labeled PET Tracer Candidates for Imaging of the Abelson Non-receptor Tyrosine Kinase in Parkinson’s Disease. Journal of Medicinal Chemistry. 2023. doi:10.1021/acs.jmedchem.3c00902
BibTeX
@article{Sten2023,
author = {Stéen, E Johanna L and Park, A Yeong and Beaino, Wissam and Gadhe, Changdev Gorakshnath and Kooijman, Esther and Schuit, Robert C and Schreurs, Maxime and Leferink, Prisca and Hoozemans, Jeroen J M and Kim, Jae Eun and Lee, Jinhwa and Windhorst, Albert D},
title = {Development of 18 F-Labeled PET Tracer Candidates for Imaging of the Abelson Non-receptor Tyrosine Kinase in Parkinson’s Disease},
journal = {Journal of Medicinal Chemistry},
year = {2023},
doi = {10.1021/acs.jmedchem.3c00902}
}
EUVIMED